Alligator Bioscience AB (publ) (ATORX.ST)
SEK 0.27
(-3.79%)
SEK 0.27
(-3.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 106.59 Million SEK | 32.36% |
| 2022 | 80.53 Million SEK | 58.13% |
| 2021 | 50.92 Million SEK | 38.79% |
| 2020 | 36.69 Million SEK | -30.28% |
| 2019 | 52.63 Million SEK | 32.08% |
| 2018 | 39.84 Million SEK | 58.89% |
| 2017 | 25.07 Million SEK | 1.96% |
| 2016 | 24.59 Million SEK | 27.52% |
| 2015 | 19.28 Million SEK | -34.12% |
| 2014 | 29.27 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 138.66 Million SEK | 30.09% |
| 2024 Q3 | 167.77 Million SEK | 28.99% |
| 2024 Q2 | 130.07 Million SEK | -6.2% |
| 2023 FY | 106.59 Million SEK | 32.36% |
| 2023 Q2 | 102.11 Million SEK | 6.89% |
| 2023 Q1 | 95.53 Million SEK | 18.63% |
| 2023 Q3 | 102.2 Million SEK | 0.09% |
| 2023 Q4 | 106.59 Million SEK | 4.3% |
| 2022 Q2 | 58.22 Million SEK | 3.03% |
| 2022 FY | 80.53 Million SEK | 58.13% |
| 2022 Q4 | 80.53 Million SEK | 28.24% |
| 2022 Q3 | 62.79 Million SEK | 7.85% |
| 2022 Q1 | 56.51 Million SEK | 10.97% |
| 2021 Q4 | 50.92 Million SEK | 8.83% |
| 2021 FY | 50.92 Million SEK | 38.79% |
| 2021 Q3 | 46.79 Million SEK | 41.01% |
| 2021 Q2 | 33.18 Million SEK | -3.69% |
| 2021 Q1 | 34.45 Million SEK | -6.1% |
| 2020 Q4 | 36.69 Million SEK | -3.04% |
| 2020 Q2 | 41.53 Million SEK | -5.5% |
| 2020 FY | 36.69 Million SEK | -30.28% |
| 2020 Q1 | 43.94 Million SEK | -16.49% |
| 2020 Q3 | 37.84 Million SEK | -8.88% |
| 2019 FY | 52.63 Million SEK | 32.08% |
| 2019 Q4 | 52.63 Million SEK | -1.69% |
| 2019 Q3 | 53.53 Million SEK | 16.28% |
| 2019 Q2 | 46.03 Million SEK | 4.43% |
| 2019 Q1 | 44.08 Million SEK | 10.63% |
| 2018 Q4 | 39.84 Million SEK | 49.33% |
| 2018 Q3 | 26.68 Million SEK | -0.64% |
| 2018 Q2 | 26.85 Million SEK | 17.28% |
| 2018 Q1 | 22.9 Million SEK | -8.68% |
| 2018 FY | 39.84 Million SEK | 58.89% |
| 2017 Q1 | 14.55 Million SEK | -40.83% |
| 2017 Q3 | 21.51 Million SEK | -0.87% |
| 2017 FY | 25.07 Million SEK | 1.96% |
| 2017 Q2 | 21.7 Million SEK | 49.18% |
| 2017 Q4 | 25.07 Million SEK | 16.53% |
| 2016 FY | 24.59 Million SEK | 27.52% |
| 2016 Q4 | 24.59 Million SEK | 97.6% |
| 2016 Q3 | 12.44 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2015 Q4 | 19.28 Million SEK | 0.0% |
| 2015 FY | 19.28 Million SEK | -34.12% |
| 2014 FY | 29.27 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Ziccum AB (publ) | 6.38 Million SEK | -1568.676% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -4418.652% |
| BioArctic AB (publ) | 139.5 Million SEK | 23.589% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -208.051% |
| Mendus AB (publ) | 51.22 Million SEK | -108.092% |
| Genovis AB (publ.) | 98.04 Million SEK | -8.718% |
| Intervacc AB (publ) | 21.68 Million SEK | -391.674% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -299.113% |
| Active Biotech AB (publ) | 13.4 Million SEK | -695.485% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 14.022% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -561.382% |
| Aptahem AB (publ) | 8.99 Million SEK | -1084.675% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -160.885% |
| Kancera AB (publ) | 17.97 Million SEK | -492.919% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -130.825% |
| Fluicell AB (publ) | 8.91 Million SEK | -1095.681% |
| Saniona AB (publ) | 86.08 Million SEK | -23.828% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -1966.596% |
| Biovica International AB (publ) | 34.76 Million SEK | -206.598% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -813.567% |
| AcouSort AB (publ) | 10.37 Million SEK | -927.125% |
| Xintela AB (publ) | 14.01 Million SEK | -660.578% |
| Abliva AB (publ) | 16.78 Million SEK | -535.212% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 50.329% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -821.385% |
| OncoZenge AB (publ) | 1.69 Million SEK | -6173.985% |
| Amniotics AB (publ) | 10.54 Million SEK | -910.667% |
| 2cureX AB (publ) | 2.93 Million SEK | -3531.857% |
| CombiGene AB (publ) | 4.15 Million SEK | -2464.847% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -2308.382% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 93.192% |
| Camurus AB (publ) | 414.81 Million SEK | 74.303% |
| Corline Biomedical AB | 6.78 Million SEK | -1470.113% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -73.729% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -456.225% |
| I-Tech AB | 16.2 Million SEK | -557.791% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 91.012% |
| Cyxone AB (publ) | 4.69 Million SEK | -2170.878% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -699.782% |
| Biosergen AB | 5.08 Million SEK | -1996.264% |
| Cantargia AB (publ) | 54.97 Million SEK | -93.915% |
| NextCell Pharma AB | 13.68 Million SEK | -678.688% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -48.358% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -674.022% |
| Nanologica AB (publ) | 79.32 Million SEK | -34.374% |
| SynAct Pharma AB | 51.83 Million SEK | -105.647% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -1240.986% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -1951.899% |
| LIDDS AB (publ) | 3.75 Million SEK | -2737.993% |
| Lipum AB (publ) | 7.53 Million SEK | -1314.102% |
| BioInvent International AB (publ) | 90.45 Million SEK | -17.846% |
| Alzinova AB (publ) | 9.33 Million SEK | -1042.375% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 41.302% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -5841.75% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -476.376% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -2677.358% |
| Simris Alg AB (publ) | 148.93 Million SEK | 28.43% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -49.885% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 77.893% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -736.433% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -1368.251% |